3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Docetaxel
19
pembrolizumab
14
Surveys and Questionnaires
7
Radiotherapy
7
Paclitaxel
7
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Standard of Care
6
Specimen Handling
6
Radiosurgery
6
Psychiatric Rehabilitation
6
Early Intervention, Educational
6
Trastuzumab
5
Nivolumab
5
enzalutamide
4
Interviews as Topic
4
motexafin gadolinium
3
cabozantinib
3
X-Rays
3
Sirolimus
3
Methods
3
Educational Status
3
Cisplatin
3
Carboplatin
3
Azacitidine
3
tisotumab vedotin
2
rucaparib
2
pertuzumab
2
pegilodecakin
2
palbociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Solutions
×
Thoracic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled